Tacrolimus 0.03% ointment in labial discoid lupus erythematosus: A randomized, controlled clinical trial

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of clinical pharmacology

• Publication date

  2015-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jcph.537PMID 25951426
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Spectrum of Cutaneous Manifestations in Systemic Lupus Erythematosus and Novel Classification

  2016cited by this paper
• Long-term clinical and cost-effectiveness of psychological intervention for family carers of people with dementia: a single-blind, randomised, controlled trial.

  2014cited by this paper
• Oral lichenoid tissue reactions: diagnosis and classification

  2014cited by this paper
• Oral manifestations of lupus erythematosus - report of two cases.

  2013cited by this paper
• Diagnostic aids for detection of oral precancerous conditions

  2013cited by this paper
• Efficacy of intralesional betamethasone for erosive oral lichen planus and evaluation of recurrence: a randomized, controlled trial.

  2013influential reference
• High-risk variants of cutaneous squamous cell carcinoma in patients with discoid lupus erythematosus: a case series

  2013cited by this paper
• Treatment of symptomatic oral lichen planus (OLP) with 0.1% tacrolimus powder in Oraguard-B - A pilot prospective study.

  2012cited by this paper
• Efficacy and safety of dexamethasone ointment on recurrent aphthous ulceration.

  2012cited by this paper
• Oral discoid lupus erythematosus: A study of twenty-one cases

  2012cited by this paper
• Malignant potential of oral and labial chronic discoid lupus erythematosus: a clinicopathological study of 87 cases

  2011cited by this paper
• Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial.

  2011cited by this paper
• Four cases of facial discoid lupus erythematosus successfully treated with topical pimecrolimus or tacrolimus.

  2010cited by this paper
• Squamous cell carcinoma in a patient with oral lichen planus treated with topical application of tacrolimus.

  2010cited by this paper
• Topical tacrolimus and pimecrolimus in the treatment of oral lichen planus: an update.

  2010cited by this paper
• Possible involvement of T lymphocytes in the pathogenesis of Nagashima‐type keratosis palmoplantaris

  2009cited by this paper
• Early Diagnosis and Treatment of Discoid Lupus Erythematosus

  2009cited by this paper
• The efficacy of topical intralesional BCG-PSN injection in the treatment of erosive oral lichen planus: a randomized controlled trial.

  2009cited by this paper
• Molecular mechanisms of corticosteroid resistance.

  2008cited by this paper
• Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double‐blind, bilateral comparison study

  2007cited by this paper
• Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study.

  2007cited by this paper
• Painless periungual pyogenic granulomata associated with reverse transcriptase inhibitor therapy in a patient with human immunodeficiency virus infection

  2007cited by this paper
• A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment.

  2006cited by this paper
• Triamcinolone acetonide mouth rinses for treatment of erosive oral lichen planus: efficacy and risk of fungal over-infection.

  2006cited by this paper
• Successful treatment with topical tacrolimus in four cases of discoid lupus erythematosus

  2006cited by this paper
• The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report

  2006cited by this paper
• 0.1% tacrolimus ointment in the treatment of discoid lupus erythematosus.

  2005cited by this paper
• Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin‐homing cytotoxic lymphocytes associated with strong expression of the type I interferon‐induced protein MxA

  2005cited by this paper
• Refractory Erosive Oral Lichen Planus Associated with Hepatitis C: Response to Topical Tacrolimus Ointment

  2005cited by this paper
• Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative.

  2004cited by this paper
• Long-term efficacy and safety of topical tacrolimus in the management of ulcerative/erosive oral lichen planus.

  2003cited by this paper
• Systemic sclerosis after interferon‐alfa therapy for myeloproliferative disorders

  2002cited by this paper
• The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus

  2002cited by this paper
• Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus.

  2002cited by this paper
• An open trial of topical tacrolimus for erosive oral lichen planus.

  2002cited by this paper
• The spectrum of cutaneous manifestations in lupus erythematosus—the Italian experience

  2000cited by this paper
• Cutaneous lupus erythematosus — A study of clinical and laboratory prognostic factors in 65 patients

  1995cited by this paper
• Tacrolimus: a new immunosuppressive agent.

  1995cited by this paper
• Effectiveness of a low dose of cyclosporine in the management of patients with oral erosive lichen planus.

  1995cited by this paper
• Oral discoid lupus erythematosus. I. The validity of previous histopathologic diagnostic criteria.

  1984cited by this paper
• The 1982 revised criteria for the classification of systemic lupus erythematosus.

  1982cited by this paper
• Abnormal laboratory test results and their relationship to prognosis in discoid lupus erythematosus. A long-term follow-up study of 92 patients.

  1979cited by this paper
• Development of squamous cell carcinoma in chronic discoid lupus erythematosus

  1978cited by this paper

• Signaling pathways and targeted interventions for precancers

  2026cites this paper
• Tacrolimus ointment: summarizing two decades of experience in off-label use. Use in rosacea, seborrheic dermatitis, papulosquamous dermatoses, lupus erythematosus, eczematous dermatoses, alopecia, and other diseases

  2026cites this paper
• Efficacy and safety of calcineurin inhibitors in cutaneous lupus: a systematic review and brief meta-analysis of recommended concentration, type, and outcomes

  2025influential citation
• Cutaneous lupus erythematosus — from pathogenesis to targeted therapy

  2025cites this paper
• Treatment of Cutaneous Lupus Erythematosus: An Evidence-Based Review

  2025influential citation
• Comparative Evaluation of Tacrolimus 0.1% in Orabase and Triamcinolone Acetonide 0.1% in the Management of Recurrent Apthous Stomatitis (RAS) – A Case Control Study

  2024cites this paper
• Efficient topical treatments of cutaneous lupus erythematosus: A systematic review and network meta-analysis.

  2024cites this paper
• Efficacy of topical tacrolimus monotherapy against pediatric discoid lupus erythematosus

  2024cites this paper
• Role of Anifrolumab in Refractory Cutaneous Manifestations of Lupus Erythematosus: A Case Series and Literature Review

  2023cites this paper
• zVAD alleviates experimental autoimmune hepatitis in mice by increasing the sensitivity of macrophage to TNFR1-dependent necroptosis.

  2022cites this paper
• Modulation of Immune Cells as a Therapy for Cutaneous Lupus Erythematosus

  2022cites this paper
• Management of Atopic Dermatitis: The Role of Tacrolimus

  2022cites this paper
• Red and White Lesions of the Oral Mucosa

  2021cites this paper
• S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics

  2021cites this paper
• Autoimmune Diseases with Oral Manifestations in Children: A Systematic Review

  2021cites this paper
• S2k‐Leitlinie zur Diagnostik und Therapie des kutanen Lupus erythematodes – Teil 2: Therapie, Risikofaktoren und spezielle Fragestellungen

  2021cites this paper
• Management of cutaneous manifestations of lupus erythematosus: A systematic review.

  2020cites this paper
• Tacrolimus 0.03% ointment treatment in exfoliative cheilitis: a randomised controlled clinical trial and monitoring blood concentration.

  2020cites this paper
• Systemic Lupus Erythematosus

  2020cites this paper
• Cutaneous Lupus Erythematosus: Progress and Challenges

  2020cites this paper
• Topical tacrolimus with different frequency for exfoliative cheilitis: a pilot study

  2020cites this paper
• Systemic and Biologic Agents for Lupus Erythematosus

  2018cites this paper
• Calcineurin inhibitors in systemic lupus erythematosus.

  2017cites this paper
• A Randomized, Double-Blinded Placebo Controlled Crossover Study Evaluating 0.03% Tacrolimus Ointment Monotherapy in the Treatment of Discoid Lupus Erythematosus in Dogs

  2017cites this paper
• Oral Ulcers in Juvenile-Onset Systemic Lupus Erythematosus: A Review of the Literature

  2017cites this paper
• Drugs for discoid lupus erythematosus.

  2017cites this paper
• Étude retrospective de l'efficacité du tacrolimus dans les langues géographiques algiques

  2015cites this paper